In a report released yesterday, Ritu Baral from Cowen & Co. maintained a Buy rating on Insmed (INSM), with a price target of $56.00. The company’s shares closed last Monday at $15.52, close to its 52-week low of $15.33.
According to TipRanks.com, Baral is a 4-star analyst with an average return of 4.4% and a 37.7% success rate. Baral covers the Healthcare sector, focusing on stocks such as Global Blood Therapeutics, Milestone Pharmaceuticals, and Madrigal Pharmaceuticals.
Currently, the analyst consensus on Insmed is a Strong Buy with an average price target of $50.63.
See today’s analyst top recommended stocks >>
The company has a one-year high of $34.94 and a one-year low of $15.33. Currently, Insmed has an average volume of 1.23M.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Insmed, Inc. is a biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Its first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. The MAC lung disease is a rare and often chronic infection that can cause irreversible lung damage and can be fatal. Its earlier-stage clinical pipeline includes INS1007, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases, and INS1009, an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for rare pulmonary disorders, including pulmonary arterial hypertension. The company was founded in 1988 and is headquartered in Bridgewater, NJ.
